Literature DB >> 19452568

Stage-specific cancer incidence: an artificially mixed multinomial logit model.

Solomon Chefo1, Alex Tsodikov.   

Abstract

Early detection of prostate cancer using the prostate-specific antigen test led to a sharp spike in the incidence of the disease accompanied by an equally sharp improvement in patient prognoses as evaluated at the point of advanced diagnosis. Observed outcomes represent age at diagnosis and stage, a categorical prognostic variable combining the actual stage and the grade of tumor. The picture is summarized by the stage-specific cancer incidence that represents a joint survival-multinomial response regressed on factors affecting the unobserved history of the disease before diagnosis (mixture). Fitting the complex joint mixed model to large population data is a challenge. We develop a stable and structured MLE approach to the problem allowing for the estimates to be obtained iteratively. Factorization of the likelihood achieved by our method allows us to work with only a fraction of the model dimension at a time. The approach is based on generalized self-consistency and the quasi-EM algorithm used to handle the mixed multinomial part of the response through Poisson likelihood. The model provides a causal link between the screening policy in the population and the stage-specific incidence. Copyright 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19452568      PMCID: PMC2779845          DOI: 10.1002/sim.3615

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  11 in total

1.  Role of transurethral resection of the prostate in population-based prostate cancer incidence rates.

Authors:  R M Merrill; E J Feuer; J L Warren; N Schussler; R A Stephenson
Journal:  Am J Epidemiol       Date:  1999-10-15       Impact factor: 4.897

Review 2.  Analysing the temporal effects of age, period and cohort.

Authors:  T R Holford
Journal:  Stat Methods Med Res       Date:  1992       Impact factor: 3.021

3.  Overdiagnosis in early detection programs.

Authors:  Ori Davidov; Marvin Zelen
Journal:  Biostatistics       Date:  2004-10       Impact factor: 5.899

4.  Semiparametric models: a generalized self-consistency approach.

Authors:  A Tsodikov
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2003-08-01       Impact factor: 4.488

5.  Forward and backward recurrence times and length biased sampling: age specific models.

Authors:  Marvin Zelen
Journal:  Lifetime Data Anal       Date:  2004-12       Impact factor: 1.588

6.  A population model of prostate cancer incidence.

Authors:  A Tsodikov; A Szabo; J Wegelin
Journal:  Stat Med       Date:  2006-08-30       Impact factor: 2.373

7.  Generalized Self-Consistency: Multinomial logit model and Poisson likelihood.

Authors:  Alex Tsodikov; Solomon Chefo
Journal:  J Stat Plan Inference       Date:  2008       Impact factor: 1.111

8.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

9.  Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.

Authors:  Angela B Mariotto; Ruth Etzioni; Martin Krapcho; Eric J Feuer
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

10.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Authors:  Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

View more
  5 in total

1.  The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.

Authors:  Ruth Etzioni; Roman Gulati; Alex Tsodikov; Elisabeth M Wever; David F Penson; Eveline A M Heijnsdijk; Jeffrey Katcher; Gerrit Draisma; Eric J Feuer; Harry J de Koning; Angela B Mariotto
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

2.  What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.

Authors:  Roman Gulati; Elisabeth M Wever; Alex Tsodikov; David F Penson; Lurdes Y T Inoue; Jeffrey Katcher; Shih-Yuan Lee; Eveline A M Heijnsdijk; Gerrit Draisma; Harry J de Koning; Ruth Etzioni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05       Impact factor: 4.254

3.  The impact of PLCO control arm contamination on perceived PSA screening efficacy.

Authors:  Roman Gulati; Alex Tsodikov; Elisabeth M Wever; Angela B Mariotto; Eveline A M Heijnsdijk; Jeffrey Katcher; Harry J de Koning; Ruth Etzioni
Journal:  Cancer Causes Control       Date:  2012-04-10       Impact factor: 2.506

Review 4.  Prostate cancer in young men: an important clinical entity.

Authors:  Claudia A Salinas; Alex Tsodikov; Miriam Ishak-Howard; Kathleen A Cooney
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

5.  The role of lifestyle characteristics on prostate cancer progression in two active surveillance cohorts.

Authors:  A D Vandersluis; D E Guy; L H Klotz; N E Fleshner; A Kiss; C Parker; V Venkateswaran
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-06-28       Impact factor: 5.554

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.